The Experts below are selected from a list of 37620 Experts worldwide ranked by ideXlab platform
Shunmugiah Karutha Pandian - One of the best experts on this subject based on the ideXlab platform.
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant Gram-positive and Gram-negative biofilms. The Bacterial Extract (50 μg ml−1) of S6-01 (Bacillus indicus = MTCC 5559) showed 80–90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80–95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, 1H NMR, and 13C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10–15 μg ml−1) showed potential activity against a wide range of biofilm...
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant gram-positive and gram-negative biofilms. The Bacterial Extract (50 μg ml(-1)) of S6-01 (Bacillus indicus = MTCC 5559) showed 80-90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80-95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, (1)H NMR, and (13)C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10-15 μg ml(-1)) showed potential activity against a wide range of biofilms. This study for the first time, reports a novel anti-biofilm compound from a marine bacterium with wide application in medicine and the aquaculture industry.
Uc Oppermann - One of the best experts on this subject based on the ideXlab platform.
-
characterization of a 3 alpha hydroxysteroid dehydrogenase carbonyl reductase from the gram negative bacterium comamonas testosteroni
FEBS Journal, 1996Co-Authors: Uc OppermannAbstract:A new form of the NAD(P)-dependent 3α-hydroxysteroid dehydrogenases (3α-HSDs), present in the gram-negative bacterium Comamonas testosteroni ATCC 11996, was isolated from a testosterone-induced Bacterial Extract and characterized. The enzyme (HSD 28) has a monomeric molecular mass of 28 kDa. It belongs to the protein superfamily of short-chain dehydrogenases/reductases (SDR) as established by N-terminal sequence analysis. Along with the 3α-hydroxysteroid dehydrogenase and 3-oxo-reductase activities towards a variety of cis or trans fused A/B ring steroids, it also reduces several xenobiotic carbonyl compounds, including a metyrapone-based class of insecticides, to the respective alcohol metabolites. No dihydrodiol dehydrogenase activity towards trans- or cis-benzene-dihydrodiols could be detected, thus distinguishing it from the indomethacine-sensitive, mammalian liver type 3α-HSDs. Subcellular fractionation revealed that the enzyme is localized in the cytoplasm of the Bacterial cell. Proteins similar to the 3α-HSD were detected and characterized from Comamonas testosteroni strain ATCC 17454 and from a commercially available steroid-induced Extract of a patent Pseudomonas strain. The N-terminal amino acid sequence of the 3α-HSD from the latter strain (HSD 29) is highly similar (94% identity over 15 residues) to a previously determined primary structure of a Pseudomonas species 3α-HSD. However, no similarities could be detected between HSD 28 and a recently determined 3α-HSD sequence from the ATCC 11996 Comamonas strain. The specific crossreaction of antibodies directed against mammalian liver type I 11β-hydroxysteroid dehydrogenase (11β-HSD I) with the isolated 3α-HSDs suggests the existence of a functionally and structurally related subgroup within the SDR superfamily. The broad substrate specificities of the characterized 3α-HSD enzymes lead to the conclusion that they might participate in the intestinal bioactivation or inactivation of hormones, bile acids and xenobiotics since Comamonas testosteroni and related species are found in the intestinal tract of vertebrates including man.
-
Characterization of a 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase from the gram-negative bacterium Comamonas testosteroni.
'Wiley', 1996Co-Authors: Uc Oppermann, Maser EAbstract:A new form of the NAD(P)-dependent 3 alpha-hydroxysteroid dehydrogenases (3 alpha-HSDs), present in the gram-negative bacterium Comamonas testosteroni ATCC 11996, was isolated from a testosterone-induced Bacterial Extract and characterized. The enzyme (HSD 28) has a monomeric molecular mass of 28 kDa. It belongs to the protein superfamily of short-chain dehydrogenases/reductases (SDR) as established by N-terminal sequence analysis. Along with the 3 alpha-hydroxysteroid dehydrogenase and 3-oxo-reductase activities towards a variety of cis or trans fused A/B ring steroids, it also reduces several xenobiotic carbonyl compounds, including a metyrapone-based class of insecticides, to the respective alcohol metabolites. No dihydrodiol dehydrogenase activity towards trans- or cis-benzene-dihydrodiols could be detected, thus distinguishing it from the indomethacine-sensitive, mammalian liver type 3 alpha-HSDs. Subcellular fractionation revealed that the enzyme is localized in the cytoplasm of the Bacterial cell. Proteins similar to the 3 alpha-HSD were detected and characterized from Comamonas testosteroni strain ATCC 17454 and from a commercially available steroid-induced Extract of a patent Pseudomonas strain. The N-terminal amino acid sequence of the 3 alpha-HSD from the latter strain (HSD 29) is highly similar (94% identity over 15 residues) to a previously determined primary structure of a Pseudomonas species 3 alpha-HSD. However, no similarities could be detected between HSD 28 and a recently determined 3 alpha-HSD sequence from the ATCC 11996 Comamonas strain. The specific crossreaction of antibodies directed against mammalian liver type I 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD I) with the isolated 3 alpha-HSDs suggests the existence of a functionally and structurally related subgroup within the SDR superfamily. The broad substrate specificities of the characterized 3 alpha-HSD enzymes lead to the conclusion that they might participate in the intestinal bioactivation or inactivation of hormones, bile acids and xenobiotics since Comamonas testosteroni and related species are found in the intestinal tract of vertebrates including man
Chari Nithya - One of the best experts on this subject based on the ideXlab platform.
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant Gram-positive and Gram-negative biofilms. The Bacterial Extract (50 μg ml−1) of S6-01 (Bacillus indicus = MTCC 5559) showed 80–90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80–95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, 1H NMR, and 13C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10–15 μg ml−1) showed potential activity against a wide range of biofilm...
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant gram-positive and gram-negative biofilms. The Bacterial Extract (50 μg ml(-1)) of S6-01 (Bacillus indicus = MTCC 5559) showed 80-90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80-95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, (1)H NMR, and (13)C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10-15 μg ml(-1)) showed potential activity against a wide range of biofilms. This study for the first time, reports a novel anti-biofilm compound from a marine bacterium with wide application in medicine and the aquaculture industry.
Muthu Gokila Devi - One of the best experts on this subject based on the ideXlab platform.
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant Gram-positive and Gram-negative biofilms. The Bacterial Extract (50 μg ml−1) of S6-01 (Bacillus indicus = MTCC 5559) showed 80–90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80–95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, 1H NMR, and 13C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10–15 μg ml−1) showed potential activity against a wide range of biofilm...
-
a novel compound from the marine bacterium bacillus pumilus s6 15 inhibits biofilm formation in gram positive and gram negative species
Biofouling, 2011Co-Authors: Chari Nithya, Muthu Gokila Devi, Shunmugiah Karutha PandianAbstract:Biofilm formation is a critical problem in nosocomial infections and in the aquaculture industries and biofilms show high resistance to antibiotics. The aim of the present study was to reveal a novel anti-biofilm compound from marine bacteria against antibiotic resistant gram-positive and gram-negative biofilms. The Bacterial Extract (50 μg ml(-1)) of S6-01 (Bacillus indicus = MTCC 5559) showed 80-90% biofilm inhibition against Escherichia coli, Shigella flexneri, Proteus mirabilis and S6-15 (Bacillus pumilus = MTCC 5560) showed 80-95% biofilm inhibition against all the 10 tested organisms. Furthermore, they also reduced the hydrophobicity index and extracellular polymeric substances (EPS) production. Structural elucidation of the active principle in S6-15 using GC-MS, (1)H NMR, and (13)C NMR spectral data revealed it to be 4-phenylbutanoic acid. This is the first report of 4-phenylbutanoic acid as a natural product. The purified compound (10-15 μg ml(-1)) showed potential activity against a wide range of biofilms. This study for the first time, reports a novel anti-biofilm compound from a marine bacterium with wide application in medicine and the aquaculture industry.
Florence Baron-papillon - One of the best experts on this subject based on the ideXlab platform.
-
Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating Bacterial Extract (OM-85 BV).
PharmacoEconomics, 2003Co-Authors: Jean-jacques Pessey, Françoise Mégas, Benoît Arnould, Florence Baron-papillonAbstract:Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences.
-
Prevention of Recurrent Rhinopharyngitis in At-Risk Children in France: A Cost-Effectiveness Model for a Nonspecific Immunostimulating Bacterial Extract (OM-85 BV)
2026Co-Authors: Jean-jacques Pessey, Françoise Mégas, Benoît Arnould, Florence Baron-papillonAbstract:Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The probability of progression of the infection and of its associated care, the principal direct costs linked to them, and the effectiveness of OM-85 BV were established or calculated by reviewing the available literature (published between 1984 and 2000). Four experts validated the parameters and the model. Results: For the French Social Security System, the mean direct cost for an acute rhinopharyngitis (ARP) infection was Conclusion: Non-specific immunotherapy should be considered for the child at risk of RARP and administered in addition to other recommended measures. The economic savings for the community of using a medication for which the clinical effectiveness has been demonstrated should also be taken into account in assessing its usefulness.Antibronchitic-Bacterial-vaccine, Children, Cost-effectiveness, Otorhinolaryngological-infections, Pharmacoeconomics, Vaccines